12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Capesaris: Phase II started

In September, GTx said it began the open-label, U.S. Phase II G200712 trial to evaluate 125, 250 or 500 mg oral Capesaris daily in about 75 men with metastatic CRPC maintained on primary androgen deprivation therapy (ADT). In...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >